KBI Biopharma Inc. sell "Cell Line Development"

KBI Biopharma provides cell line development spanning mammalian and microbial expression platforms to speed biotherapeutic development from gene to GMP. Its mammalian offering includes CHO-M Selexis SUREtechnology, CHO-ZN, CHO-DG44, CHO-S, and CHO-K1 GS platforms for robust, scalable, high-titer lines suited to complex molecules like mAbs, Fc-fusion proteins, and ADCs, while its microbial offering uses E. coli-based platforms, including off-the-shelf and engineered strains, for early-stage material or scalable production of peptides, enzymes, and other recombinant proteins, letting clients pick the expression system that best fits their molecule's complexity and clinical timeline.